Karen Miotto, M.D.


Director, UCLA Addiction Psychiatry Service

Associate Professor, Psychiatry and Biobehavioral Sciences

Member, Adult Psychiatry

Contact Information

Work Phone Number: (310) 206-2782

Mailing Address:

UCLA Psychr & Biobehav Sci
BOX 951759, 760 Westwood Plaza, B8-233A Semel Institute
Los Angeles, CA 90095



A selected list of publications:

Ling Walter, Hillhouse Maureen, Jenkins Jessica, Miotto Karen, Torrington Matthew, Chapleo Christopher   Comparisons of Analgesic Potency and Side Effects of Buprenorphine and Buprenorphine With Ultra-low-dose Naloxone Journal of addiction medicine, 2012; 6(2): 118-23.
Miotto Karen, Kaufman Aaron, Kong Alexander, Jun Grace, Schwartz Jeffrey   Managing co-occurring substance use and pain disorders The Psychiatric clinics of North America, 2012; 35(2): 393-409.
Miotto Karen, Hillhouse Maureen, Donovick Roger, Cunningham-Rathner Jerry, Charuvastra Charlie, Torrington Matthew, Esagoff Asher E, Ling Walter   Comparison of buprenorphine treatment for opioid dependence in 3 settings Journal of addiction medicine, 2012; 6(1): 68-76.
Ray Lara A, Bujarski Spencer, Chin Pauline F, Miotto Karen   Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012; 37(2): 445-55.
Ray Lara A, Chin Pauline F, Heydari Andia, Miotto Karen   A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving Psychopharmacology, 2011; 217(3): 341-51.
Zorick Todd, Mandelkern Mark A, Lee Buyean, Wong Ma-Li, Miotto Karen, Shabazian Jon, London Edythe D   Elevated plasma prolactin in abstinent methamphetamine-dependent subjects The American journal of drug and alcohol abuse, 2011; 37(1): 62-7.
Zorick Todd, Nestor Liam, Miotto Karen, Sugar Catherine, Hellemann Gerhard, Scanlon Graham, Rawson Richard, London Edythe D   Withdrawal symptoms in abstinent methamphetamine-dependent subjects Addiction (Abingdon, England), 2010; 105(10): 1809-18.
Walwyn Wendy M, Miotto Karen A, Evans Christopher J   Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions Drug and alcohol dependence, 2010; 108(3): 156-65.
Ray Lara A, Chin Pauline F, Miotto Karen   Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics CNS & neurological disorders drug targets, 2010; 9(1): 13-22.
Zorick Todd, Sevak Rajkumar J, Miotto Karen, Shoptaw Steven, Swanson Aimee-Noelle, Clement Clayton, De La Garza Richard, Newton Thomas F, London Edythe D   Pilot Safety Evaluation of Varenicline for the Treatment of Methamphetamine Dependence Journal of experimental pharmacology, 2009; 2010(2): 13-18.
Al Ghananeem Abeer M, Herman Barbara H, Abbassi Maggie, Yu Elmer, Miotto Karen, O'Brien Charles P, Ling Walter, Montgomery Ann, Walsh Robert   Urine and plasma pharmacokinetics of lofexidine after oral delivery in opiate-dependent patients The American journal of drug and alcohol abuse, 2009; 35(5): 311-5.
Yu Elmer, Miotto Karen, Akerele Evaristo, Montgomery Ann, Elkashef Ahmed, Walsh Robert, Montoya Ivan, Fischman Marian W, Collins Joseph, McSherry Frances, Boardman Kathy, Davies David K, O'Brien Charles P, Ling Walter, Kleber Herbert, Herman Barbara H   A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal Drug and alcohol dependence, 2008; 97(1-2): 158-68.
Yu Elmer, Miotto Karen, Akerele Evaristo, O'Brien Charles P, Ling Walter, Kleber Herbert, Fischman Marian W, Elkashef Ahmed, Herman Barbara H, Al-Ghananeem Abeer M   Clinical pharmacokinetics of lofexidine, the alpha 2-adrenergic receptor agonist, in opiate addicts plasma using a highly sensitive liquid chromatography tandem mass spectrometric analysis The American journal of drug and alcohol abuse, 2008; 34(5): 611-6.
Rawson Richard A, McCann Michael J, Flammino Frank, Shoptaw Steven, Miotto Karen, Reiber Chris, Ling Walter   A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals Addiction (Abingdon, England), 2006; 101(2): 267-74.
Maglione Margaret, Miotto Karen, Iguchi Martin, Hilton Lara, Shekelle Paul   Psychiatric symptoms associated with ephedra use Expert opinion on drug safety, 2005; 4(5): 879-84.
Maglione Margaret, Miotto Karen, Iguchi Martin, Jungvig Lara, Morton Sally C, Shekelle Paul G   Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events The American journal of psychiatry, 2005; 162(1): 189-91.
Compton Peggy, Miotto Karen, Elashoff David   Precipitated opioid withdrawal across acute physical dependence induction methods Pharmacology, biochemistry, and behavior, 2004; 77(2): 263-8.
London Edythe D, Simon Sara L, Berman Steven M, Mandelkern Mark A, Lichtman Aaron M, Bramen Jennifer, Shinn Ann K, Miotto Karen, Learn Jennifer, Dong Yun, Matochik John A, Kurian Varughese, Newton Thomas, Woods Roger, Rawson Richard, Ling Walter   Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers Archives of general psychiatry, 2004; 61(1): 73-84.
Miotto Karen, McCann Michael, Basch Janice, Rawson Richard, Ling Walter   Naltrexone and dysphoria: fact or myth? The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions, 2002; 11(2): 151-60.
Freese Thomas E, Miotto Karen, Reback Cathy J   The effects and consequences of selected club drugs Journal of substance abuse treatment, 2002; 23(2): 151-6.